English (United Kingdom) español 中文 (中国) Türkçe 日本語 ไทย

Helping you to practise evidence-based medicine

Editorial Archive

Our Editorial Archive features a collection of editorial commentaries from experts in the field of evidence-based medicine, and critical appraisal of important clinical research.

2008

Identifying and prioritising HTA research that is important to the NHS

Like any organisation, the NHS needs to evolve to meet the needs of its customers. But how does a large service provider like the NHS identify areas in which it could improve, as well as gaps in its knowledge? The National Institute for Health Research Health Technology Assessment programme plays a key role in this process, as outlined in our Editorial by Nicholas Hicks, Pamela Young, and Naomi Stockley.

download this editorial [36KB]
by Nicholas Hicks, Pamela Young & Naomi Stockley, September 10th, 2008

Do old treatments need a new EBM?

Are all treatments equal in the eyes of EBM? In terms of systematic reviews and RCTs — perceived as the cornerstones of EBM today — the answer is no. But, as Helen Barnett and Ike Iheanacho discuss in their Editorial, systematic reviews and RCTs are not necessarily the best sources for identifying clinically useful treatments. Moves to implement a different type of research strategy for long-established interventions return to the spirit of EBM — building on the best available evidence and clinical expertise, while considering patients’ experiences and values.

download this editorial [38KB]
by Helen Barnett & Ike Iheanacho, August 28, 2008

Adverse effects of a treatment may be turned to our advantage

Is a mild adverse effect of a drug treatment always an undesirable event? Or can an adverse effect be exploited to elicit a beneficial effect in another condition? In our Editorial, we touch on this question using a recent study of amitriptyline in the treatment of diarrhoea-predominant irritable bowel syndrome. As we highlight, the distinction between contributions from beneficial and adverse effect is not always clear.

download this editorial [139KB]
by Sam Love, August 18, 2008

Do athletes and WADA differ in their perception of caffeine as a performance-enhancing drug?

Caffeine is probably the most commonly consumed stimulant worldwide. Four years ago, before the Athens Olympics, the World Anti-Doping Agency (WADA) took this substance off its list of drugs prohibited in sport. With the Beijing Olympics beginning next month, we contemplate how the change in WADA's thinking on the performance-enhancing effects of caffeine has influenced elite athletes' perceptions of the powers of this stimulant.

download this editorial [37KB]
by Mark Stuart, July 28, 2008

Improving child health using evidence, when little exists

In resource-rich countries, chronic paediatric illnesses are rare. But this low prevalence has contributed to the lack of an evidence base for children as comprehensive as that available for adults. It may be that, as discussed by Michael Silverstein and Howard Bauchner, considering children with chronic conditions separately from those without them could help to remedy this gap in the evidence.

download this editorial [33KB]
by Michael Silverstein & Howard Bauchner, July 14, 2008

The challenge of reducing postpartum haemorrhage-related deaths

Strategies to reduce morbidity and mortality from postpartum haemorrhage in resource-poor settings are determined by the resources available to a community. But does the evidence support the strategies implemented? In our Guest Editorial, Metin Gülmezoglu and Justus Hofmeyr review gaps in the evidence, and suggest that focusing on community interventions could be the way forward.

download this editorial [46KB]
by A. Metin Gülmezoglu & G. Justus Hofmeyr, June 16, 2008

Diarrhoea prevention: can the way a systematic review is conducted prevent early and effective introduction of low-cost public health interventions?

All reviewers need to make the best of their time and resources. But can restricting the search still best serve the needs of the review? In our editorial, Alan Thomas compares two reviews on low-cost public health interventions in the prevention of diarrhoea (our review of diarrhoea in adults has been recently updated). He contemplates that consideration of the impact of the results of the review on people's lives is perhaps just as important as the choice of the search methods and outcomes assessed.

download this editorial [234KB]
by Alan Thomas, May 27, 2008

Surrogate v clinical: what's the outcome?

How much can blood pressure tell us about a treatment for stroke? Or bone mineral density about fracture-prevention strategies? Using surrogate outcomes as a substitute for clinical events may not always give us the complete picture of treatment effectiveness. In our Editorial, Samantha Barton discusses how their use can raise more questions than answers, and contemplates what makes an ideal surrogate outcome.

download this editorial [93KB]
by Samantha Barton, May 05, 2008

Complementary medicine and evidence: like fire and water?

New evidence on complementary medicine is now regularly being included in high-quality systematic reviews. EBM practitioners' opinions in this area and the evidence behind it are famously divided and often low. They range from the point of view that there is virtually no usable evidence to the conclusion that traditional scientific evidence is just not well-suited to complementary medicine. In our Guest Editorial, Professor Edzard Ernst discusses the reasons behind these doubts, and what can be done to strengthen confidence in this therapeutic area.

download this editorial [75KB]
by Edzard Ernst, April 21, 2008

When evidence is a luxury: treating drug-resistant tuberculosis

Multidrug-resistant tuberculosis (MDR-TB) has been reported across the world, and its incidence is rising: according to the WHO, there were 500,000 cases of MDR-TB in 2006. Population heterogeneity, the wide array of available treatment regimens, and characterisation of resistance all complicate the development of evidence-based treatment guidelines. But, as Philip Hopewell and Ernesto Jaramillo highlight, combining data from the available scientific literature with clinical expertise and experience from MDR-TB treatment programmes can create a foundation on which a management scheme for this infection can be built.

download this editorial [95KB]
by Philip C. Hopewell & Ernesto Jaramillo, March 24, 2008

Subarachnoid haemorrhage: still a diagnostic headache for emergency physicians

Subarachnoid haemorrhage is challenging to diagnose. Evidence-based guidelines are lacking, but computed tomography followed by lumbar puncture is recommended as the appropriate strategy. Negative results for both tests have been found to be sufficient to rule out diagnosis. However, although this combination is sensitive, it has been reported to lack specificity. There is encouraging evidence that diagnosis of this condition will be easier in the future, but, as highlighted in our Editorial by Alastair Newton and Andrew Parfitt, sometimes clinical experience makes the difference.

download this editorial [81KB]
by Alastair Newton & Andrew Parfitt, March 10, 2008

Bell's palsy: are commonly used treatments effective?

Consensus treatment, based on expert opinion, for early stages of Bell's palsy comprises a corticosteroid plus an antiviral agent. However, recent evidence suggests that although corticosteroids have a small, but significant, benefit when started within 72 hours of onset, antivirals confer no more benefit than placebo. Should clinical practice for the treatment of this condition be revised on the basis of this finding? In our Editorial, a critical appraisal by Karen Pettersen suggests that perhaps combination treatment should not be abandoned just yet.

download this editorial [91KB]
Karen Petterson, February 25, 2008

How often do researchers address questions of interest to clinicians and patients?

Many health questions are important to clinicians and patients, but cannot be answered by research evidence available today. In a guest editorial, Iain Chalmers, coordinator of the James Lind initiative, asks whether researchers are making sufficient effort to respond to clinician and patient need when designing research protocols.

download this editorial [75KB]
Iain Chalmers, January 28, 2008

BMJ Clinical Evidence makes the GRADE

2007 has been an outstanding year for BMJ Clinical Evidence. In addition to producing new systematic reviews and updating those already published, we have introduced a method based on the work of the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) working party for assessing the quality of the research we review, and have also published an amazing variety of Letters from the Editor. In the latest Letter, we explain more about how we have implemented the GRADE evaluation process for BMJ Clinical Evidence reviews, and revisit two Letters which have encouraged us reconsider our editorial approach.

download this editorial [76KB]
Charles Young & Alison Martin, January 02, 2008

2007

Using evidence to inform HIV/AIDS-prevention policy and practice in Africa: challenges and opportunities

Sub-Saharan Africa is home to more than two thirds of all people infected with HIV: a grim statistic considering that most people in this region do not have access to antiretroviral therapy. Preventing HIV infection in Africa is therefore a global health care priority. This month, Nandi Siegfried and Don Operario discuss the challenges ahead for those charged with developing and implementing evidence-based HIV-preventative strategies in Africa. For further information on HIV in resource poor countries, please see our reviews on Managing HIV/AIDS in resource poor settings.

download this editorial [84KB]
Nandi Siegfried & Don Operario, December 03, 2007

Chemotherapy-induced toxicity in the community oncology setting: hear no evil, see no evil

It’s always exciting to read about promising new anti-cancer drugs, and physicians are naturally eager to make use of these therapies in everyday practice. Justin Stebbing, George Dranitsaris and Mark Vincent highlight how the toxicity of drugs tested in the ideal settings of clinical trials can sometimes be underestimated. They discuss strategies to minimise the risks of using new chemotherapies in the community, including a website that can help clinicians predict the chances of adverse effects in individual patients.

download this editorial [99KB]
Justin Stebbing, George Dranitsaris & Mark Vincent, November 19, 2007

Getting behind the headlines: Helping the public make sense of medical news

The mainstream media love to report good news about miracle cures that often turn out to be not so wonderful when the absolute benefit to an individual is known. In her editorial, Cherrill Hicks discusses the problem of overenthusiastic reporting, and how a new service from BMJ BestTreatments will help healthcare professionals and patients get beneath the hype to develop realistic expectations about new interventions.

download this editorial [79KB]
Cherrill Hicks, November 05, 2007

Screening for breast cancer in the 21st century

Routine screening mammography is recommended for all UK women aged 50 to 70 years, as there is general consensus that screening women for breast cancer in middle age saves lives. Recently, the UK Government announced an extension of the age range for screening to include women aged 47 to 73 years, reviving the dispute about the value of routine mammography for younger women. In her editorial, Professor Valerie Beral considers this debate as she reviews the challenges facing today's breast cancer screening programmes. To read about interventions for breast cancer, see the BMJ Clinical Evidence Reviews: Breast cancer (metastatic) and Breast cancer (non-metastatic).

download this editorial [80KB]
Valerie Beral, October 15, 2007

Evidence gets personal

One of the most important tenets of evidence-based medicine is recognition of the importance of patients’ values and preferences in determining the use of evidence within the consultation. In practice, the ways in which trials are constructed, conducted and reported frequently cause problems for clinicians and patients who wish to implement research evidence from clinical studies in practice. In his editorial, David Tovey reports from the James Lind Alliance/Lancet conference held at the Royal Society in London, which brought together a panel of experts to discuss the challenges of personalising evidence.

download this editorial [139KB]
David Tovey, September 17, 2007

Does vitamin D prevent heart disease? A comparison of two trials

The role of vitamins in preventing cardiovascular disease (CVD) has recently been addressed in several interesting papers. An RCT just published in Archives of Internal Medicine has shown that vitamins C, E and beta carotene do not protect women at high risk of CVD. Similarly, two recent studies have investigated the link between vitamin D and CVD. Here, we discuss the findings from the vitamin D trials, illustrating how researchers can best use different types of trial design to effectively answer important clinical questions.

download this editorial [77KB]
Mark Stuart, September 03, 2007

Interim analysis: its uses and limitations

Emerging data in clinical trials are often previewed to ensure the safety of participants and to optimise the benefits derived from trials. Recently, an interim analysis of the RECORD trial — a large RCT assessing the cardiovascular effects of rosiglitazone — was published in the New England Journal of Medicine in response to a meta-analysis that cast doubt on rosiglitazone’s cardiovascular safety. Here, Dirk Bassler, Victor Montori, and Gordon Guyatt discuss whether the RECORD interim analysis has exonerated rosiglitazone, and outline the uses and limitations of data preview.

download this editorial [101KB]
Dirk Bassler, Victor M. Montori & Gordon Guyatt, August 15, 2007

Is the onset of action of antidepressants truly delayed?

There are now many treatment options for people with depressive disorders (see our recently updated review on Depression in adults — drug and other physical treatments. But despite the rapid pace of drug development in mental health, one important question about antidepressant drugs remains unanswered: how long do people usually take to respond to these agents? Here, Andrea Cipriani, Corrado Barbui, and John Geddes discuss the challenges of designing trials to investigate the timing of onset of action of antidepressant drugs.

download this editorial [82KB]
Andrea Cipriani, Corrado Barbui & John R. Geddes, July 16, 2007

Lung cancer risk and workplace exposure to environmental tobacco smoke

On July 1 2007, England became officially "smoke-free" with smoking forbidden in virtually all enclosed public places. The ban was enforced because of the risk of smoking-related diseases, particularly lung cancer, in people working in smoky venues, such as pubs and bars. In our letter from the editor, we discuss the evidence base behind the smoking ban, focusing on a recent meta-analysis that has investigated the link between passive smoking at work and lung cancer.

download this editorial [76KB]
Damian Pattinson, July 02, 2007

Delirium at the end of life

This month, we launch the BMJ Clinical Evidence Supportive and palliative care section, which systematically reviews the evidence base behind these two distinct, but complementary, medical specialities. Here, Sam Ahmedzai and Paul Keeley explain the challenges of finding and collating evidence for supportive and palliative care. In line with the inclusive remit of today's supportive care physicians, our new section will include reviews covering a broad range of clinical problems, initially Constipation in people prescribed opioids, Delirium at the end of life, and Nausea and vomiting in people with cancer and other chronic diseases.

download this editorial [77KB]
Sam H Ahmedzai & Paul W Keeley, June 18, 2007

Hormone replacement therapy and cardiovascular risk

Although the Women’s Health Initiative Study suggested that hormone replacement therapy (HRT) may increase the risk of coronary heart disease in postmenopausal women, the effects of HRT on cardiovascular disease, particularly in women in early menopause, remain controversial. A recent study in JAMA tackles this issue, asking if the cardiovascular effects of HRT vary with age or with proximity to menopause. In our Letter from the Editor we discuss whether the JAMA study brings us any closer to resolving this controversy.

download this editorial [89KB]
Shannon Amoils, June 04, 2007

Obesity in children

Childhood obesity is a growing health problem in resource rich countries. Government imperatives to tackle childhood obesity place a burden on clinical and public health professionals, especially as information on the effectiveness and costs of interventions has been difficult to find. The new BMJ Health Intelligence website provides information on management of childhood obesity from a public health and commissioning perspective, while the new BMJ Clinical Evidence review on childhood obesity presents the evidence on interventions for use with individual patients.

download this editorial [76KB]
Alison Walker, May 15, 2007

Updating the evidence: what difference does it make?

BMJ Clinical Evidence provides clinicians with the best available evidence in the face of rapidly evolving clinical practice. To achieve this, we regularly reappraise the evidence for our systematic reviews. But does such a rigorous and intensive approach to updating reviews result in increased knowledge? Or should updating be more selective and driven by the likelihood of finding new evidence? See the Letter from the Editor where we present our research into how much actually changes when we update our systematic reviews.

download this editorial [77KB]
Alex McNeil & Alan Thomas, May 01, 2007

Applying principles of evidence based medicine to the delivery of clinical care for people with HIV in resource limited settings

Although resource poor countries bear the greatest burden of HIV disease, little research into HIV/AIDS has actually been conducted in these settings. Considering the differences in demographic distribution, co-morbidities and care infrastructure, it cannot be assumed that conclusions drawn from resource rich countries can be applied to resource poor settings. Commissioned by Johnson and Johnson, and in association with the Liverpool School of Tropical Medicine, BMJ Clinical Evidence presents a series of systematic reviews focusing on the challenges of managing HIV/AIDS in resource limited settings.

download this editorial [92KB]
Angela Obasi, April 16, 2007

Evidence-based medicine: old school versus new school

The increasing availability of sophisticated information resources that identify and appraise high-quality evidence from the medical literature has meant that today’s clinicians can practice evidence-based medicine (EBM) without necessarily acquiring critical appraisal skills. But, as Brian Haynes and Charles Young discuss in the Letter from the Editor, there is no room for complacency — the term EBM is often misused and clinicians must retain the ability to distinguish between true and spurious evidence-based resources.

download this editorial [70KB]
Brian Haynes & Charles Young, April 02, 2007

High dose pralidoxime in acute organophosphorus pesticide poisoning

Organophosphorus pesticides are possibly the most widely used means of deliberate self harm and occupational poisoning in Asia and Central America. Until recently there has been little evidence of benefit from any intervention designed to treat organophosphorus poisoning, and mortality rates have remained high (see our recently updated systematic review on acute organophosphorus poisoning). We now appraise a key study, published after our review, which shows that a continuous infusion of high dose pralidoxime may reduce mortality compared with standard treatment regimens.

download this editorial [85KB]
Alison Martin & Charles Young, March 19, 2007

Is combination treatment best for depression in adolescents?

The treatment of adolescents with major depressive disorder is fraught with challenges and uncertainties. Concerns about adverse effects of antidepressants in this group have discouraged physicians from prescribing drug therapy and, in addition, relatively little is known about the efficacy of cognitive and other psychological therapies. We have recently updated our review on depression in children and adolescents and we now appraise the Treatment for Adolescents with Depression Study (TADS), a large RCT which provides evidence that combined drug and psychological treatment may be the best treatment strategy.

download this editorial [84KB]
Alison Martin, Charles Young & David Tovey, March 05, 2007

Can exercise prevent the common cold?

BMJ Clinical Evidence identifies important clinical questions, produces systematic reviews of valid research data which answer these questions, and presents the reviews in a way that is accessible and informative for clinicians. We aim to fully update each of our systematic reviews annually and, in addition, we provide new links on a continuous basis to important research papers published prior to each update. In considering how best to use the Letter from the Editor section on the homepage we felt that, in addition to publishing occasional editorial views on aspects of evidence based practice, we would also highlight interesting publications identified by our continuous updating service such as the paper by Chubak and colleagues about exercise & the common cold.

download this editorial [72KB]
Shannon Amoils, Karen Pettersen & Charles Young, February 19, 2007